Physicians should think about regardless of whether their sufferers with underlying NAION hazard aspects could be adversely afflicted by use of PDE5 inhibitors. Individuals who have already seasoned NAION are at improved risk of NAION recurrence. As a result, PDE5 inhibitors, which include LEVITRA, ought to be utilised with warning in these people